CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03110744|
Recruitment Status : Completed
First Posted : April 12, 2017
Last Update Posted : March 27, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Chordoma||Drug: Palbociclib||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||43 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601)|
|Actual Study Start Date :||December 15, 2017|
|Actual Primary Completion Date :||December 22, 2022|
|Actual Study Completion Date :||December 22, 2022|
application on 21 consecutive days of a 28 days cycle
application on 21 consecutive days of a 28 days cycle
Other Name: Ibrance
- Disease control rate (DCR) [ Time Frame: 6 months ]The primary endpoint is the DCR after six cycles of palbociclib, which is defined as the presence of at least one confirmed complete response (CR) or confirmed partial response (PR) or stable disease (SD) according to RECIST version 1.1.
- Tumor response rate (TRR) [ Time Frame: 6 months ]• defined as the sum of complete remission (CR) and partial remission (PR) according to RECIST version 1.1 after six cycles of study medication.
- Progression-free survival (PFS) [ Time Frame: 6 months ]• defined as the time from first administration of the Investigational Medicinal Product (IMP) to radiologically confirmed progression of disease or death from any cause, whichever occurs first. Patients without the event are censored on the last date of follow-up.
- Overall survival (OS) [ Time Frame: 6 months ]• defined as the time from first administration of the IMP to time of death from any cause. Patients without the event are censored on the last date of follow-up.
- Safety (toxicity, tolerability): Toxic effects will be graded according to CTCAE v4.03. [ Time Frame: 6 months ]• Toxic effects will be graded according to CTCAE v4.03.
- Quality of life (QoL) [ Time Frame: 6 months ]• QoL will be assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases and demographics initially, after the first, and after the sixth 28-day treatment cycle
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients with locally advanced or metastatic chordoma with confirmed diagnosis in a reference pathology (with immunohistology for epithelial membrane antigen, S100, Brachyury, Integrase interactor 1 (INI-1)) not amenable to curative treatment with surgery or radiotherapy
- At least one measurable tumor lesion according to RECIST 1.1 criteria
- Loss of p16 determined immunohistochemically or CDKN2A/B genomically, presence of CDK4/6 and RB1 determined immunohistochemically or by RNA-Sequencing.
- Age ≥ 18 years, no upper age limit
- Availability of tissue blocks preferably not older than 12 months for immunohistologic assessment (if no adequate material is available, re-biopsy should be considered before entering the study)
- No chemotherapy two weeks before study
- Non-pregnant and non-nursing. Women of child-bearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 72 hours prior to registration (WOCBP is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 months).
- Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (double barrier contraceptive method (IUD, condome), tubal ligation, or partner's vasectomy) while on therapy and for 14 weeks after the last dose of therapy. Hormonal contraception alone is an inadequate method of birth control. Female patients must agree not to donate lactation during treatment and until 14 weeks after end of treatment.
- Men must agree not to father a child and must use a latex condom during any sexual contact with WOCBP while receiving therapy and for 14 weeks after therapy is stopped, even if they have undergone successful vasectomy. Sperm donation is not permitted for the same time interval.
- Signed written informed consent
- Performance status ≤ 2 according to Eastern Cooperative Oncology Group (ECOG) /World Health Organization (WHO) criteria
- Ability of patient to understand the character and individual consequences of clinical trial
- Prior treatment with palbociclib or known intolerance/allergy to the compound or any ingredient (acquired or hereditary).
- Prior treatment with other CDK4/6 inhibitors
- Co-therapy with strong/potent CYP3A inducers and/or inhibitors, (e.g., Clarithromycin, Indinavir, Itraconazol, Ketoconazol, Lopinavir/Ritonavir, Nefazodon, Nelfinavir, Posaconazol, Saquinavir, Telaprevir, Telithromycin, Voriconazol, and St. John's Wort [Hypericum perforatum])) while on treatment with study drug.
- Co-therapy with corticosteroids above 7.5 mg prednisolone/prednisone equivalent
- Anticancer treatment less than 2 weeks prior to study treatment
- Organ insufficiency: creatinine clearance <30ml/min; total bilirubin > 1.5x upper normal serum level; AST > upper normal serum level ; abnormal blood counts; heart failure (New York Heart Association (NYHA) III/IV); uncontrolled hypertension; unstable angina; serious cardiac arrhythmia; severe obstructive or restrictive ventilation disorder
- Clinical signs of active infection (° grade 2-CTCAE Vers.5.0)
- Patients with a "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if the patients have completed therapy and are considered by the patients physician to be at less than 30% risk of relapse within one year.
- Severe neurologic or psychiatric disorder interfering with ability of giving informed consent
- Known or suspected active alcohol or drug abuse
- Known positivity for HIV, active hepatitis A virus (HAV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
- Uncontrolled central nervous system (CNS) involvement (treatment for CNS-involvement prior to inclusion is allowed)
- Cytopenia: platelets <100 G/l, neutrophils <1.0 G/l, hemoglobin <10.0 g/dl
- corrected QT interval (QTc) >470 msec (based on the mean value of triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome, or known history of QTc prolongation or Torsade de Pointes
- Uncontrolled electrolyte disorders that can aggravate the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)
- Participation in other ongoing interventional clinical trials
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03110744
|Essen, Germany, 45147|
|National Center for Tumor Diseases|
|Heidelberg, Germany, 69120|
|Ulm, Germany, 89081|
|Principal Investigator:||Stefan Fröhling, Prof. Dr.||NCT Heidelberg|
Documents provided by Prof. Dr. Richard F Schlenk, University Hospital Heidelberg:
|Responsible Party:||Prof. Dr. Richard F Schlenk, Prof. Dr. med. Richard F. Schlenk (Coordinating Investigator), University Hospital Heidelberg|
|Other Study ID Numbers:||
NCT-2016-415 / Chordoma
|First Posted:||April 12, 2017 Key Record Dates|
|Last Update Posted:||March 27, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Protein Kinase Inhibitors
Molecular Mechanisms of Pharmacological Action